Evaluation of SAVED/IMPEDE risk assessment models for VTE prophylaxis in multiple myeloma patients
Files
Publication Date
4-29-2026
Keywords
oregon, ppmc, ppmc gme, ppmc gme pharmacy
Disciplines
Medical Education
Abstract
Abstract: Venous thromboembolism (VTE) is a significant complication in patients with multiple myeloma. The National Comprehensive Cancer Network (NCCN) Multiple Myeloma guidelines recommend administering VTE prophylaxis for eligible patients if there are no contraindications to anticoagulation or antiplatelet agents. Current VTE prophylaxis recommendations are guided by the SAVED and IMPEDE scores, which are tools used to predict the risk of VTE in patients with multiple myeloma. The primary purpose is to determine the incidence of VTE, stratified by IMPEDE/SAVED score, in patients with multiple myeloma receiving treatment at Providence Cancer Institute Franz Clinic. EPIC will be queried using SlicerDicer to identify patients diagnosed with multiple myeloma who are actively receiving treatment at Providence Cancer Institute Franz Clinic. Exclusion criteria include research participants, patients already on an anticoagulation or antiplatelet agent for other prescribed indications, and patients not being actively treated for multiple myeloma. A report will be generated that includes potential patients for study inclusion. Additional reports will be generated to identify patients who have a VTE diagnosis, on aspirin or an anticoagulation agent, and other variables that are important for IMPEDE/SAVED score calculation such as age, immunomodulatory drug therapy, Asian race, BMI, pelvic/hip/femur diagnosis, surgery within the last 90 days, erythropoiesis-stimulating agents, dexamethasone dose, doxorubicin, tunneled line or central venous catheter, and existing thromboprophylaxis (therapeutic or prophylaxis). The IMPEDE/SAVED score will be calculated for patients to identify whether patients were on an appropriate prophylactic agent, indexed to their Cycle 1, Day 1 treatment, based on the calculated IMPEDE/ SAVED score per NCCN guidelines. For patients with a VTE diagnosis, it will be determined if the VTE occurred before or after the initiation of multiple myeloma treatment. Adverse events related to VTE prophylaxis (clinically relevant bleeding) will also be reported. IRB status is exempt. Data is currently being collected. Results and conclusions will be shared when the project is completed. Presentation category: Hematology/oncology/immunology/transplant
Specialty/Research Institute
Graduate Medical Education
Specialty/Research Institute
Pharmacy
